Early in the COVID-19 pandemic, concerns were raised about the safety of angiotensin receptor blockade in patients with the COVID-19 infection, as it may alter ACE2 expression and therefore enhance virulence, transmission and disease severity [24,25], an issue that later was found to not be clinically apparent [26,27]. This evidence concerns the gene ACE2 and COVID-19.